In a significant move, the Drug Enforcement Administration (DEA) has extended the telehealth flexibilities that allow physicians and other prescribers to prescribe controlled substances without an in-person evaluation till the end of 2024. The telemedicine flexibilities, which were initially put into place in response to the pandemic, were first introduced in March 2020. With just over a month left for the expiration of the first set of these flexibilities, the DEA announced the extension, as reported on JD Supra.
This move is welcomed by both patients and healthcare providers who had been heavily reliant on telehealth services in the wake of the ongoing global health crisis. The DEA’s extension not only extends the affordable and convenient care to patients who benefit greatly from it; but it also supports healthcare providers by offering them a recognized, authorized, and regulated avenue for meeting health needs.
Despite this positive development, there are important legal considerations for those in the health care sector. These relaxations by the DEA are temporary and the future may see the return of restrictions. It will therefore be important to monitor any potential legislative or regulatory changes in this area to ensure compliance.
As we move closer to the end of 2024, it will be seen whether such flexibilities become a cornerstone of healthcare delivery in the future. It will be interesting to watch how the regulators deal with the benefits and challenges posed by telehealth services, and whether they continue to play a role in how medicines, including controlled substances, are prescribed.